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Eight recurrences manifested with clinical symptoms and 4 
were detected during follow-up or during a diagnostic work-
up for clinical symptoms caused by distant metastases. 
Treatment modalities were surgery, chemotherapy, radio-
therapy, and bacillus Calmette-Guérin urethral instillations. 
Nine patients died of cancer. The median survival after the 
diagnosis of UR was 6 months.  Conclusions: UR after RC with 
an orthotopic neobladder in females is rare. Solitary, nonin-
vasive recurrences have a favorable prognosis when detect-
ed early. Invasive recurrences are often associated with local 
and distant metastases and have a poor prognosis. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 In recent decades, radical cystectomy (RC) with extend-
ed pelvic lymph node dissection has become the mainstay 
of treatment for muscle-invasive bladder cancer. The treat-
ment aims to provide long-term survival with an acceptable 
quality of life. Reconstruction of the lower urinary tract us-
ing orthotopic bladder substitution has increased the ac-
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 Abstract 
 Introduction: The incidence, treatment, and outcome of 
urethral recurrence (UR) after radical cystectomy (RC) for 
muscle-invasive bladder cancer with orthotopic neobladder 
in women have rarely been addressed in the literature.  Pa-
tients and Methods: A total of 12 patients (median age at 
recurrence: 60 years) who experienced UR after RC with an 
orthotopic neobladder were selected for this study from a 
cohort of 456 women from participating institutions. The pri-
mary clinical and pathological characteristics at RC, includ-
ing the manifestation of the UR and its treatment and out-
come, were reviewed.  Results: The primary bladder tumors 
in the 12 patients were urothelial carcinoma in 8 patients, 
squamous cell carcinoma and adenocarcinoma in 1 patient 
each, and mixed histology in 2 patients. Three patients (25%) 
had lymph node-positive disease at RC. The median time 
from RC to the detection of UR was 8 months (range 4–55). 
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ceptance of radical surgical treatment by both physicians 
and patients  [1] , including older age groups  [2, 3] .
 The initial reluctance to perform orthotopic bladder 
substitution in females was due to the short urethral length 
(hence, the proximity of the bladder neck and bladder tu-
mor) and the fear of incontinence after removal of the 
proximal urethra adjacent to the bladder neck  [4] . The 
added morbidity of urethrectomy, the longer surgical 
time, and the very high rate of negative pathology made 
physicians question the need for routine urethrectomy in 
females  [5] . This paved the way for a wider use of ortho-
topic neobladders in women. According to recent ana-
tomical dissection studies, the external female rhabdo-
sphincter is located in the distal half of the urethra and is 
innervated by the pudendal nerve from below. Smooth 
muscle innervated by the autonomic nerve system via 
branches from the pelvic plexus running alongside the lat-
eral vaginal walls is present throughout the length of the 
urethra. Hence, a careful technique of bladder neck and 
vaginal dissection will preserve the nerve supply and mus-
cle structures necessary for continence  [6] .
 Retrospective pathological studies have reported a 12% 
(range 6–46) rate of concomitant tumor (of any stage) in 
the bladder and the urethra in females. Bladder neck in-
volvement is a strong risk factor for concomitant urethral 
malignancy, observed in 19–33% of urethral tumors. In 
contrast, urethral tumors have never been found in women 
with a tumor-free bladder neck. Some investigators found 
an association with tumor involvement of the anterior vag-
inal wall, but later studies failed to confirm this finding  [4] .
 We describe the incidence, treatment, and outcomes 
in 12 cases of recurrence of urinary bladder cancer (UBC) 
in the female urethra after RC.
 Patients and Methods 
 The 12 patients reported herein were selected from a multi-
institutional collaborative cohort of 456 women who underwent 
RC for UBC in 1 of the 5 participating centers between 1994 and 
2011. The median follow-up was 64 months (range 3–196). We 
retrospectively reviewed the clinical and pathological records of all 
456 female patients for age, histology, tumor stage and grade, 
lymph node involvement, soft-tissue surgical margins, final ure-
thral margin status, and survival  [7] . 
 The intensity of the follow-up depended on each institution’s 
protocol. Recurrence in the surgical bed was defined as local, recur-
rence at distant organs was defined as distant, and recurrence in the 
urethra was defined as urethral. Clinical outcomes were measured 
from the date of cystectomy to the date of the first documented re-
currence, the date of death, or the date of the last follow-up if the 
patient had not experienced disease recurrence. A positive urethral 
margin was a significant risk factor for urethral recurrence (UR)  [7] .
 The present report describes the 12 recurrent patients identi-
fied within the defined cohort, including 1 who relapsed after the 
end of the original study ( table 1 ). 
 Results 
 A total of 12 patients (median age at RC: 58 years; range 
41–71) were studied. The bladder tumors were urothelial 
carcinoma in 8 patients (67%), squamous cell and adeno-
carcinoma in 1 patient (8%) each, and mixed urothelial 
carcinoma in 2 patients (17%). Three patients had lymph 
node-positive disease (2 with pN1 and 1 with pN2) at RC, 
and none had evidence of distant metastasis at RC (cM0). 
Urinary diversion was performed according to Studer or 
Hautmann (6 cases each). Two patients (G and L) received 
adjuvant cisplatin-based chemotherapy after RC.
 The median time from RC to the detection of recur-
rence in the urethra was 8 months (range 4–55). Eight 
recurrences (67%) manifested with clinical symptoms 
which were pain-related in 4 patients, bleeding in 3, gross 
hematuria in 2, and urinary retention in 2. One recur-
rence was seen protruding from the urethra. The remain-
der were detected during follow-up or during a diagnostic 
work-up for clinical symptoms caused either by synchro-
nous distant metastases or by pelvic recurrence.
 Treatment with curative intent was given to 6 patients, 
and treatment with a palliative intent to was given to 3. 
Three women were unfit for or refused treatment. Open 
surgery was performed in 5 patients (including urinary 
undiversion in 3), radiotherapy was performed in 2 pa-
tients, chemotherapy was performed in 3 patients, and 
bacillus Calmette-Guérin (BCG) urethral instillations 
were used in 2 patients. Nine women (75%) died of cancer 
and 3 were still alive at the time of reporting. The median 
survival after detection of UR was 6 months (range 2–15). 
The most frequent sites of distant metastases were lymph 
nodes and bones.
 Discussion 
 In our study, we gathered 12 cases of UR after RC with 
a neobladder substitution in women. This number is too 
low for statistically meaningful conclusions, but several 
observations can be made. 
 The advantage of maintaining a natural voiding pat-
tern after RC must be weighed against the risk of a subse-
quent tumor recurrence in the remnant urethra. An 8.1% 
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a meta-analysis of unselected male patients (256 of 3,165 
cases). UR after RC in females with an orthotopic neo-
bladder is much less common  [8] . Rates as low as 0% have 
been reported, albeit in small and/or short follow-up 
studies ( table 2 ).
 Risk factors including multifocality, primary tumor 
stage and grade, the presence of carcinoma in situ (CIS), 
and upper urinary tract involvement have been reported 
 [5] . The most consistent association has been observed 
between the type of diversion and UR risk: patients with 
a neobladder are less likely to develop a secondary ure-
thral tumor than those with a cutaneous diversion  [9–12] .
 One of the reasons for the lower UR incidence in wom-
en compared to men may be the fact that squamous cell 
mucosa (normal or metaplastic) covers a large portion of 
the female urethra and the demarcation line between 
squamous and transitional epithelium moves cranially 
with increasing age  [8] . Only 5 cases of UR in the retained 
urethra after RC with a neobladder in women have been 
described to date  [13–17] . 
 Generally, a positive urethral surgical margin at RC is 
considered to be a contraindication for neobladder and 
should prompt a urethrectomy  [18] . Cases have been re-
ported in the literature, however, where urethral margin 
positivity at the final histopathology was not associated 
with disease recurrence  [19] or resulted in a pT0 status at 
re-exploration  [13] . All of our patients who died of the 
disease had a concomitant pelvic recurrence or distant 
 Table 1.  Clinical and pathological characteristics of 12 female patients who experienced UR after RC and orthotopic neobladder
Pa-
tient

















P or M at
diagnosis/





A 29/05/1996 66 pT3a pN0 G3 urothelial H 8 C cT3 M 3
B 26/02/1998 55 pT2b pN0 G3 urothelial H 4 C cT3 cN3 
inoperable
M 3
C 27/02/2006 56 pTa pN0 G1 urothelial S NR C pTX G3 –/– –
D 23/06/2008 62 pT2a pN0 G3 urothelial S 7 C pT4 G3 P/M 5
E 11/09/2007 71 pTis pN0 urothelial S 21 F CIS –/– –
F 30/03/2009 64 pTis + pT3b pN0 G3 urothelial + squamous S 7 F CIS –/– –
G 12/10/2005 66 pTis + pT2b pN0 G2 urothelial S 55 W NR M 7
H 22/04/2005 63 pT2a pN0 G2–3 urothelial + adenocarcinoma S 52 W NR M 15
I 23/04/1997 51 pT3a pN0 G3 adenocarcinoma H 12 C pT1 G3 P 7
J 22/04/1995 47 pT3a pN1 G2 squamous H 8 C pT1 G3 P/M 7
K 25/02/2002 51 pTis + pT3b pN0 G3 urothelial H 13 F pT1 G3 P NR
L 13/07/2008 41 pT3a pN1 G3 urothelial H 10 C pT1 G3 P 2
 Patient A presented with bleeding, pain and acute urinary retention. At 
that time, she had already been receiving paclitaxel and radiotherapy for pu-
bic bone metastases diagnosed previously. After the detection of UR, only 
optimal supportive care was administered. Patient B had recurrence in the 
urethra, which caused pain and was palpable on physical examination. Du-
ring an attempted surgical removal, advanced disease with metastatic de-
posits was found. The urinary diversion was transformed into a Mainz pouch 
II. Soon thereafter, she developed a colocutaneous fistula and nephrostomy 
tubes had to be inserted. Patient C was diagnosed with UR originating in the 
distal urethra as detected by both ultrasonography and physical examinati-
on. After surgical removal of the recurrence, she was free of disease for the 
entire follow-up. Patient D had recurrence manifesting as a painful mass 
protruding from the urethra and causing urinary retention. Surgical treat-
ment included removal of the vagina and neobladder infiltrated by the tumor 
and conversion of the urinary diversion into an ileal conduit. The recurrence 
histology was pT4 G3 urothelial carcinoma with myxoid features. Patient E 
had UR diagnosed by urethral wash-out cytology and confirmed by a biopsy. 
She was treated with 6 urethral BCG instillations repeated every 3 – 6 months. 
She was the only one of this series to have a positive urethral margin at the 
final histopathology, yet she counts among survivors, being free of disease 
for 45 months after the operation. Patient F had her recurrence diagnosed by 
urethral cytology. The disease was eradicated via BCG instillations, but re-
lapsed again as CIS 3 years later. Conservative management with BCG was 
on-going at the time of reporting. Patient G received adjuvant gemcitabine 
+ cisplatin after RC. She presented with a subileus caused by UR originating 
from the proximal urethra and bladder neck, infiltrating the neobladder, va-
gina, and rectum. Surgical treatment was attempted with partial vaginal, ile-
al, and total rectal resection. Multiple pelvic and peritoneal metastases were 
discovered. The patient received palliative chemotherapy. Patient H had UR 
detected during a work-up for an epileptic seizure caused by a synchronous 
brain metastasis. Radiotherapy failed to control the disease and she died with 
brain and pulmonary metastases. Patient I was unfit for the treatment of her 
urethral recurrence. Patient J presented with bleeding and gross hematuria 
as symptoms of squamous cell carcinoma UR. Urethrectomy was performed 
with conversion of the neobladder to a catheterizable continent reservoir. 
Nevertheless, she died of disease progression with lymph node and osseous 
metastases. Patient K was diagnosed with UR on follow-up imaging along 
with a concomitant pelvic mass. She was unfit for curative treatment. Patient 
L received adjuvant cisplatin-based chemotherapy after RC. UR manifested 
with pain and was evident on physical examination. Palliative gemcitabine 
and radiotherapy administration followed. H = Hautmann neobladder; S = 
Studer neobladder; C = by clinical symptoms; F = during follow-up; W = 
during a work-up for unrelated clinical symptoms; P = pelvic recurrence;
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metastases at the time of UR diagnosis. Conversely, 3 fe-
males who were alive at the time of reporting had neither 
pelvic recurrence nor distant metastasis during follow-
up. The primary bladder tumor stage was a predictor of 
survival. Of the 3 survivors among our patients, 2 had 
non-muscle-invasive bladder cancer at the time of RC 
(pTis and pTa). Nine out of 10 muscle-invasive primary 
UBC were followed by UR with a concomitant pelvic 
mass and/or distant metastasis. Ultimately, all died of 
cancer.
 Surgical removal of the recurrence with a curative in-
tent was attempted in 5 of our 12 patients, but the disease 
was truly eradicated in only 1 patient (patient C). The 
neobladder had to be changed to a Mainz pouch II, an 
ileal conduit, and a catheterizable continent reservoir in 
patients B, D, and J, respectively. Recurrences in the form 
of CIS have been successfully treated with BCG instilla-
tions of the urethra; this approach was described previ-
ously by Varol et al.  [20] . When chemotherapy was ad-
ministered, it was done with a palliative intent. The lon-
gest survival (15 months) was observed in patient H, who 
was treated with radiotherapy; the time to recurrence 
and the final grade 2–3 at RC suggest that her bladder 
cancer in general had a less aggressive character. There-
fore, it seems that survival after UR treatment depends 
rather on the nature of the recurrence than on the treat-
ment modality.
 The oncological efficiency of follow-up in patients af-
ter RC is controversial  [21, 22] . In our 12 patients, UR 
were detected based on symptoms in 1 of 3 patients who 
were still alive at the time of reporting and in 6 of 9 pa-
tients who died of the disease. Those who died of aggres-
sive tumors might have – or might not have – been saved 
by earlier detection. However, we may assume that the 
2 women with urethral CIS detected at follow-up would 
likely have progressed over time to muscle-invasive dis-
ease had they not been diagnosed and treated.
 Given the easy anatomical accessibility of the female ure-
thra, it can easily be checked during follow-up after RC. At 
a minimum, the patient can be asked about a history of 
gross hematuria and/or pain on micturition, and a digital 
vaginal examination can be performed  [18] . A vaginal ul-
trasound gives excellent resolution of the urethral region. 
Introital ultrasonography might be a reasonable alternative 
but, to the best of our knowledge, no study has addressed 
this issue in a systematic manner. With regard to the CIS 
cases in our cohort and their long-term survival, urethral 
wash-out cytology  [20] can be considered at least for pa-
tients at risk (i.e. those with CIS in the primary UBC at RC). 
Because of the broad time frame (6–55 months) in which 
the UR developed in our patients, it is difficult to draw con-
clusions regarding the optimal duration and frequency of 
follow-up in women with orthotopic neobladders.
 Conclusions 
 Recurrence of a bladder tumor in the female urethra 
after RC with an orthotopic neobladder is a rare event. 
Noninvasive recurrences (pTa-1 and CIS) are usually not 
accompanied by pelvic or distant metastasis and their 
prognosis is relatively favorable with adequate treatment. 
In contrast, if UR is associated with a local or distant dis-
ease relapse, the prognosis is dismal. 
 Table 2.  UR rates in females after RC and orthotopic neobladder reported in the literature






Taylor et al., 2010 [23] 10 61 (31 – 80) 54 (1 – 187) 0
Stein et al., 2009 [19] 120 66 (33 – 83) 103 (1 – 192) 1 (0.8%)
Akkad et al., 2006 [14] 46 64 (34 – 78) 45 (2 – 138) 2 (4.3%)
Ali-El-Dein et al., 2004 [15] 145 50 (23 – 73) 17 (4 – 78) 2 (1.4%)
Hassan et al., 2004 [11] 29 63 (35 – 88) 34 (1 – 97) 0
Yamashita et al., 2003 [24] 15 NR 61 (2 – 254) 0
Yossepowitch et al., 2003 [25] 8 58 (31 – 76) 44 (1 – 153) 0
Stenzl et al., 2001 [26] 96 59 (28 – 79) 26 (2 – 100) 0
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